Expertise in
9
conditions

Katharina S. Gotze

Munich, BY, DE 
Expertise in
9
conditions
Munich, BY, DE 

Overview

Katharina Gotze practices practicing medicine in Munich, Germany.

Gotze is highly rated in 9 conditions, according to our data. Their clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Transplant, and Splenectomy.

They are actively involved in clinical research, co-authoring 174 peer reviewed articles and participating in 12 clinical trials.

Locations

Munich, BY, Germany
Other Locations
Thum, SN, Germany
Heidelberg, BW, Germany
Erlangen, BY, Germany
Leipzig, SN, Germany
Marburg An Der Lahn, HE, Germany
Hamburg, HH, Germany
Freiburg, BW, Germany
Mainz, RP 55128, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Enrollment Status: Suspended
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drugs: CA-4948, Azacitidine, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase IIIb, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Luspatercept in Patients With Lower-risk MDS and Ring-sideroblastic Phenotype (MDS-RS)
A Phase IIIb, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Luspatercept in Patients With Lower-risk MDS and Ring-sideroblastic Phenotype (MDS-RS)
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug
Study Drug: Luspatercept
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
Enrollment Status: Terminated
Publish Date: May 06, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 2
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Enrollment Status: Completed
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Dasatinib, Cytarabine, Daunorubicin, Idarubicin
Study Phase: Phase 3
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Biological, Drug
Study Drug: Flotetuzumab
Study Phase: Phase 1/Phase 2
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Enrollment Status: Completed
Publish Date: February 27, 2023
Intervention Type: Drug
Study Drug: Gemtuzumab
Study Phase: Phase 3
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM333, a CD33 Targeted Bispecific Antibody Engaging T-cells, in Relapsed or Refractory Acute Myeloid Leukemia
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM333, a CD33 Targeted Bispecific Antibody Engaging T-cells, in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: September 29, 2022
Intervention Type: Drug
Study Drug: GEM333
Study Phase: Phase 1
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)
Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)
Enrollment Status: Completed
Publish Date: November 15, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

174 Total Publications

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.
Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.
Journal: Leukemia
Published: January 31, 2026

Frequently Asked Questions about Katharina S. Gotze

Is Katharina S. Gotze a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Katharina S. Gotze is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Katharina S. Gotze participate in research or clinical trials?

Yes. Katharina S. Gotze has published 174 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Katharina S. Gotze's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Gotze's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile